1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD73

CD73

CD73 (Ecto-5′-nucleotidase), a component of the purinergic signaling pathway, is a 70-kD glycosylphosphatidylinositol-anchored cell surface protein encoded by the NT5E gene.

CD73 has both enzymatic and non-enzymatic functions in cells. As a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape. CD73 plays a crucial role in switching on adenosinergic signaling. CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other.

Overexpression of CD73 is associated with resistance to antitumor agents. Knockdown of CD73 inhibits in vitro cell growth, cell cycle progression and cell migration in many cancers. CD73 and its associated pathways may be useful as therapeutic targets.

CD73 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-100747
    PSB-12379 Inhibitor 99.99%
    PSB-12379 is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
  • HY-103695
    CD73-IN-1 Inhibitor 98.78%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
  • HY-125286
    AB-680 Inhibitor
    AB-680 is highly potent, reversible and selective small molecule inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-112502
    MethADP Inhibitor
    MethADP is a specific CD73 inhibitor.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.